Blueprint Medicines

Revised Blueprint-VantAI deal turns focus to molecular glues

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and prioritizing new target-effector pairs that could be used to develop molecular glue therapeutics.

Gabrielle Masson May 20, 2025 10:32am

Stock image of blueprints and a hard hat

Blueprint halts CDK2 inhibitor but pushes on in breast cancer

Jan 13, 2025 5:43am

Blueprint drops lung cancer programs after seeing early data

Jan 9, 2024 9:22am

permit blueprint approved rubber stamped yes check

Blueprint's solid tumor med permitted to resume trial

Mar 29, 2023 5:00am

Blueprint's solid tumor med slapped with partial clinical hold

Feb 10, 2023 10:30am

Resist resistance fight against cancer arrows out tumor immunotherapy

AACR: Blueprint wants to make resistance to Tagrisso futile

Apr 8, 2022 1:00pm